Introduction
============

*Cryptococcus neoformans* (*Cn*) is a fungal pathogen that infects humans via the respiratory tract. It is an environmental microorganism particularly present in pigeon droppings or associated with eucalyptus tree but it can be isolated from soil, water, milk, fruits, horse intestinal flora, bird nests, bats, burns, and cockroaches. Once inhaled in the lung, dissemination of the infection through the bloodstream leads to the development of a life-threatening meningoencephalitis, particularly in immunocompromised patients ([@b13]; [@b47]). An important characteristic that enables the fungus to cause disease is its ability to grow in alkaline, neutral, and acidic environments of the human body. Alkaline/neutral environments are found extracellularly, such as in alveolar spaces and in the bloodstream, whereas acidic environments are characteristically found intracellularly, within the phagolysosome of host phagocytic cells ([@b18]). Indeed, *Cn* is a facultative intracellular pathogen and can move in and out without killing host cells ([@b5]; [@b38]). In doing so, it constantly needs to adapt to a new environment, for instance, by changing the organization of different cellular components, gene expression, protein activities, or arrangements of lipids within membranes.

It might be impossible to fully understand this adaptation using a purely reductionistic approach because of continual changes in the production and degradation of key cellular components and because of the complex interplay among these components during switches in the environment. Instead, the use of systems biological methods might offer an opportunity to complement reductionistic insights by explaining complex, systemic behaviors, such as cellular adaptation to environments, through the simultaneous investigation of stimuli and responses of several enzymes and metabolites in terms of space, time, and context. The spatial aspect is important because it accounts for compartmentalization and the topographic relationships among the components; the need to consider time is evident, given the dramatic dynamic changes in the molecular characteristics during adaptation; and addressing the cellular and environmental context at each time point accounts for the interdependencies between all components partaking in the adaptation process ([@b2], [@b3]). Thus, system biology has a chance of shedding light on the complexities that govern microbial metabolic pathways, and their regulation and adaptations may ultimately allow us to predict cellular or biological phenotypes without the need for large-scale wet experimentation. Specifically for the case of *Cn*, the application of systems biological concepts may provide significant insights into the mechanisms of fungal pathogenesis and into the complex interplay between the fungus and the host immunity in chronic fungal diseases.

In all eukaryotic cells, the main intracellular pH regulator is the plasma membrane H^+^ATPase (Pma1) pump, whose activation results in proton extrusion, maintaining the intracellular pH neutral ([@b60]; [@b59]) even if the extracellular pH is acidic ([@b49]; [@b53]). In *Saccharomyces cerevisiae* (*Sc*) and in *Cn*, Pma1 is essential for cell viability ([@b62]), suggesting that Pma1 has a key role in regulating the intracellular pH. Many studies in *Sc* proposed a role for sphingolipids in the regulation of Pma1 function in the endoplasmic reticulum (ER) and at the plasma membrane ([@b46]; [@b33]; [@b70]; [@b23], [@b24]; [@b65]).

The basic structural component of sphingolipids is a long-chain sphingoid base backbone (e.g., sphingosine or phytosphingosine (PHS)). The linkage of a fatty acid to the two-amino group of this backbone through an amide bond yields ceramide or phytoceramide. Complex sphingolipids are formed with the addition of a polar group to ceramide (or phytoceramide) via an ester bond at the C-1 position. The synthesis of sphingolipid occurs in all eukaryotic cells and, in addition to being common components of membranes, they have been recognized to function as signaling molecules in a variety of signaling pathways (reviewed in [@b22]). In mammalian cells, sphingolipids such as ceramide, ceramide-1-phosphate, and sphingosine-1-phosphate have key roles in the regulation of cellular proliferation, stress responses, cell cycle, apoptosis, inflammation, and immune response (reviewed in [@b36]; [@b25]; [@b44]).

In *Cn*, sphingolipids have emerged as important molecules required for growth and signaling in alkaline/neutral ([@b35]; [@b54]; [@b55]) and acidic ([@b12]; [@b8]; [@b61]) environments. Thus, we hypothesize that when *Cn* shifts from a neutral/alkaline environment, such as extracellular alveolar spaces or the bloodstream, to an acidic environment, such as the phagolysosome of phagocytic cells, it should promote a biochemical response associated with its sphingolipid pathway, with a consequent metabolic adaptation to the new environment.

In this study, we thus developed a mathematical model of sphingolipid metabolism in the pathogenic fungus *Cn* and made reliable predictions on its biochemical sphingolipid adaptation to a shift from an alkaline to an acidic pH, mimicking the internalization of the fungus by phagocytic cells. The model was designed and analyzed within the framework of Biochemical System Theory (BST), which uses power-law representations for all enzymatic and transport processes ([@b56], [@b57], [@b58]; [@b63]).

Results
=======

The results of our studies fall into three categories. The first set describes experimental studies that identified inositol phosphorylceramide synthase (Ipc1), inositol phosphosphingolipid phospholipase C (Isc1), and phytoceramides of different lengths as important contributors to the response of *Cn* to H^+^ATPase pump (Pma1) and ATP-mediated shifts in pH. Especially the putative roles of the enzymes Ipc1 and Isc1 seem puzzling, because these enzymes catalyze opposite directions of the reversible reaction between phytoceramide and inositol phosphoryl ceramide (IPC). The second set of studies used a mathematical systems model to elucidate how the different contributors might lead to an appropriate stress response. This model in turn made predictions regarding Pma1 and the role of ATP, which we investigated experimentally in the third set of studies as model validation.

Experimental studies identifying Ipc1, Isc1, and phytoceramide as drivers of pH response
----------------------------------------------------------------------------------------

### Effect of Ipc1 downregulation and Isc1 deletion on growth of Cn in acidic environments

Inositol phosphoryl ceramide synthase 1 (Ipc1) is a fungal enzyme localized in the Golgi apparatus in *Sc* ([@b34]) and *Cn* (M Del Poeta, unpublished data). It transfers inositol phosphate from phosphatidylinositol (PI) to phytoceramide, producing IPC and 1,2-*sn*-diacylglycerol (DAG) ([@b32]; [@b27]). Isc1 is an enzyme localized in the ER and breaks down IPC, mannosyl-IPC (MIPC), and mannosyl diphosphoryl ceramide (M(IP)~2~C) to phytoceramide, inositol phosphate (MIP), and M(IP)~2~, respectively ([@b15]). We tested a mutant in which Ipc1 is downregulated, *GAL7:IPC1*, grown on glucose medium, and found that it fails to adapt with sufficient speed to an acidic environment and, as a consequence, its growth is significantly retarded ([Supplementary Figure 1A](#S1){ref-type="supplementary-material"}) ([@b37]). Similarly, a mutant strain in which Isc1 was deleted, Δ*isc1*, showed a delay in the adaptation to a low-pH environment ([Supplementary Figure 1B](#S1){ref-type="supplementary-material"}) ([@b12]; [@b8]; [@b61]). Thus, two enzymes with 'opposite\' biochemical activities (Ipc1 uses phytoceramide as a substrate and produces IPC, whereas Isc1 uses IPC as a substrate and produces phytoceramide) have the same effect on viability in changing pH environments. This puzzling finding was quite intriguing and warranted further investigations at the systems level (see 'Computational studies\').

### Measurement of phytoceramide subspecies in *Cn* wild type during growth at alkaline/neutral and acidic pH

Fungal cells produce variant species of phytoceramide that differ principally in the lengths of their acyl chains and their hydroxylation states ([@b66], [@b67]). This variability led to the question of whether phytoceramide subspecies levels would change when cells are shifted from a neutral to an acidic environment. Targeted experiments indeed revealed that in *Cn* cells exposed to a low-pH environment, the total level of non-hydroxylated phytoceramide decreases to half the level in a neutral environment (from 3862.7±6.34 to 1588.7±6.32 pmol/pmol P~i~; *P*\<0.05), whereas the total level of hydroxylated phytoceramides increases significantly compared to that in neutral pH (from 1244.1±3.2 to 2147.2±3.5 pmol/pmol P~i~) ([Table I](#t1){ref-type="table"}). Analysis of the different phytoceramide subspecies revealed that very long-chain phytoceramides (both C~26~ hydroxylated and non-hydroxylated forms) were significantly elevated at low compared to neutral pH, whereas short-chain non-hydroxylated phytoceramides (C~14~, C~16~, and C~18~) were significantly decreased at low compared to neutral pH (*P*\<0.05). Phytoceramide measurements were also performed at alkaline pH (7.4). No differences were found in phytoceramide levels or phytoceramide subspecies between pH 7.0 and 7.4 (data not shown). These results suggest that *Cn* changes the metabolism of certain phytoceramide subspecies when shifted from a neutral/alkaline to an acidic environment.

### Ebselen causes elevated inhibition in Isc1 mutant

As the plasma membrane proton pump H^+^ATPase (Pma1) is one of the major regulators of intracellular H^+^ ([@b60]; [@b59]), we wondered whether the absence of Isc1 or downregulation of Ipc1 would affect the susceptibility of yeast cells to Pma1 inhibitors. To address this question, we examined the minimal inhibitory concentration (MIC) and minimal fungicidal concentration (MFC) of ebselen, a well-established inhibitor of fungal Pma1 ([@b48]). We found that loss of Isc1 or downregulation of Ipc1 significantly increases the susceptibility of yeast cells to ebselen ([Table II](#t2){ref-type="table"}), suggesting that both Isc1 and Ipc1 may potentially regulate Pma1 function.

Computational studies
---------------------

The diagram of all reaction steps that were deemed important in the sphingolipid pathway of *Cn* and on which the model is based is presented in [Figure 1](#f1){ref-type="fig"}. Most analyses reflect the late-log phase of growth at acidic pH.

We adapted an earlier sphingolipid model for yeast ([@b7], [@b6]) to the peculiarities of *Cn*. Importantly, we incorporated several organelles that separate the physical synthesis of metabolites. Also the new model was developed during late-log phase and it contains several newly determined metabolite levels and enzyme activities in wild-type (WT) *Cn* grown at acidic pH. In addition to allowing for ceramides with different fatty acid chain lengths, the new model accounts for mechanisms of transporting protons between the cytosol and the phagolysosome, which are crucial for the survival of *Cn*. Since Pma1 trafficking ([@b23]) and function ([@b33]) are controlled by very long-chain phytoceramides, the mathematical model of *Cn* sphingolipid pathway proposed here pays particular attention to the dynamics of Pma1, as well as to short-chain and very long-chain phytoceramides and the enzymes that directly and indirectly regulate their production.

The model analyses fall into two categories. As it is standard in BST, we first diagnosed the model by thoroughly investigating its stability and robustness and evaluating sensitivities and gains, especially with respect to enzyme activities. Most of the results of these analyses are unremarkable and are therefore presented in [Supplementary information](#S1){ref-type="supplementary-material"}. The gains provided us with some insights into which metabolites are most affected by changes in particular enzymes and transport steps. However, they did not reveal compelling explanations of how *Cn* coordinates responses to shifts in pH. By contrast, exploration of the consequences of alterations in Ipc1 and Isc1 suggested interesting mechanisms of handling protons. All analyses were executed with the free software PLAS^©^ ([@b19]).

The cellular compartments involved in the model are as follows.

### Cytoplasm

We include the transport of palmitate and serine, required for the first step of sphingolipid biosynthesis. In acidic conditions, as they exist inside macrophages, protons move into the cell. The inclusion of proton transport is important for the relationships with H^+^ATPase (Pma1) and cytoplasmic pH. Proton import into the fungal cytosol is modeled as a simple (first order) transport process, whereas the export mechanism depends highly on Pma1. A simple transport process implies direct proportionality between proton influx (inside the fungus) and the external proton concentration (outside the fungus but inside the phagolysosome). Our model considers the fungal ATP synthesis and degradation ([Supplementary Table S7](#S1){ref-type="supplementary-material"}) and includes the F~0~F~1~-ATPase in the fungal mitochondria (equation 17). Our model assumes that the fungus is inside the phagolysosome (its physiological environment once internalized by host macrophages) with no direct contact with the host mitochondria. For instance, we refer to a simple transport process when the proton influx depends directly on the electrochemical gradient. By contrast, Pma1 (*X*~125~) utilizes energy obtained directly from ATP hydrolysis to transport protons against the electrochemical differences across the plasma membrane.

### Endoplasmic reticulum

The first steps of the sphingolipid pathway take place in the ER. The condensation of serine and the acyl group transferred from palmitoyl-CoA form 3-ketodihydrosphingosine (KDHS). This reaction is catalyzed by serine palmitoyltransferase ([@b12]). KDHS is rapidly converted into dihydrosphingosine (DHS). In the model, DHS can be converted by a hydroxylase to PHS. At the same time, under the action of a specific ceramide synthase (sphingoid base *N*-acyl transferase), DHS and a long-chain fatty acid CoA may form dihydroceramides C~18,~ C~24~, and C~26~. PHS may combine with long-chain fatty acid CoA to form phytoceramides C~18,~ C~24~, and C~26~. Both dihydroceramides C~18,~ C~24~, and C~26~ and phytoceramides C~18,~ C~24~, and C~26~ may undergo hydrolytic reactions to form DHS and PHS, respectively, which are catalyzed by specific ceramidases ([@b39]; [@b40]). In the model, dihydroceramide C~26~ may be hydroxylated directly to phytoceramide C~26~. Once produced, the transport of phytoceramides C~18,~ C~24~, and C~26~ from ER to Golgi apparatus follows a first-order process.

The model considers that the biosynthesis of phytoceramide and Pma1 occurs in the ER. The Pma1 in the ER compartment has an activity in response to pH signals similar to the Pma1 inserted in the plasma membrane, as previously suggested ([@b52]). The model predicts that Pma1 is stabilized by phytoceramide C~26~ produced by Isc1 ([@b33]). The model also considers Sec61, which was found to be upregulated during murine macrophage infection of *Cn* ([@b17]), a secretory factor that could mediate the insertion of Pma1 into vesicles. Pma1 travels from the ER to the Golgi apparatus and finally to the plasma membrane where it is inserted ([@b14]).

### Golgi apparatus

In the Golgi apparatus, phytoceramides C~18,~ C~24~, and C~26~ are substrates for Ipc1. Ipc1 transfers inositol phosphate from PI to phytoceramide(s), producing IPC (IPC-C~18~, -C~24~, and -C~26~) and DAG. Ipc1 is localized in the Golgi apparatus, implying that phytoceramides are transported from the ER to the Golgi apparatus.

IPC(s) can also be mannosylated, forming MIPC, and MIPC can be transformed into M(IP)~2~C by the action of inositol phosphoryl transferase 1. For simplicity, MIPC, M(IP)~2~C, and It1 are not considered in the model. Also, we hypothesize that IPC-C~26~ is transported from the Golgi apparatus to the ER and used by the ER enzyme Isc1 to produce phytoceramide C~26~. The model does not differentiate among *trans*-, medial-, and *cis*-Golgi. The synthesis of complex sphingolipids (IPCs, MIPCs, and M(IP)~2~Cs) occurs in the Golgi apparatus and their different distribution in other membranes implies the existence of a sorting mechanism for complex sphingolipids. Indeed, the presence of inositol-containing sphingolipids in organelles of the secretory pathway has been suggested ([@b26]). Synthesis and transport of sphingolipids in yeasts, especially complex sphingolipids, has been poorly studied. However, phytoceramide is indeed produced in the ER and transported to the Golgi apparatus, independent of vesicular traffic because IPC synthesis still continues when vesicular transport is blocked in *sec* mutants ([@b21]).

### Mitochondria

Mitochondria are the major producers of ATP. In yeast, the F~0~F~1~-ATP synthase is the protein that is responsible for the aerobic synthesis of ATP, and it is localized in the inner mitochondrial membrane ([@b20]). The F~1~F~0~-ATP synthase is important for the regulation of intracellular pH, implicating mitochondria as a major regulator of cytoplasmic pH ([@b42]). Although in rat liver the cytosolic-mitochondrial delta pH can be between 0.06 and 0.31 pH units when the cytosol is acidified with permeant weak acids ([@b16]), there is no much literature on *in vivo* mitochondria-cytosol pH recordings.

In *Cn*, as in other eukaryotes, ATP is derived from mitochondria respiration. During respiration, the electron transfer chain with terminal cytochrome *c* oxidase (COX) pathway generates a proton gradient, which, among other functions, powers the synthesis of ATP through F~1~F~0~-ATP synthase. In addition to this pathway, *Cn* (and other fungi, higher plants, and some protozoa) possesses a unique cyanide-resistant electron transport chain in its mitochondria. This pathway is composed of a homodimeric protein identified as an alternative oxidase 1 (Aox1) ([@b4]). As Aox1 is important for *Cn* to survive in acidic conditions, we included it in the model.

In *Sc*, Isc1 has been found in the mitochondria during the late-log phase ([@b66]). Thus, this enzyme can form phytoceramide in the mitochondria from IPC ([@b31]). Interestingly, *Sc* Δ*isc*1 mutant showed reduced levels of mitochondrial COX subunits Cox3 and Cox4 ([@b67]), suggesting that Isc1 play a role in the respiration by mitochondria.

Analytical model results
========================

The model analyses fall into two categories. As it is standard in BST, we first diagnosed the model by analyzing its stability and evaluating its robustness through computation of sensitivities and (logarithmic) gains, especially with respect to enzyme activities. Most of the results of these analyses are not particularly interesting and were therefore moved to [Supplementary information](#S1){ref-type="supplementary-material"}. The second type of analysis targets the dynamics of the system and is accomplished through simulation studies.

Eigenvalue analysis confirmed the stability of the steady state of the model. Furthermore, the system was quite robust, as measured by sensitivity and gain profiles with low magnitudes. A (logarithmic) gain quantifies the effect of a 1% change in some enzyme activity on some steady-state output quantity, such as a metabolite concentration or a flux. In the particular case of our model, no gains pointed to obvious problems or interesting control points. As in the earlier model for sphingolipid metabolism in yeast ([@b7], [@b6]), the precursors serine, palmitate, and fatty acid-CoA, as well as the initial transport and kinetic steps, by and large have the highest gains, which is intuitively reasonable because they determine the entire input to the system, while most other reactions merely redistribute material within the system. Outside the 'input mechanisms,\' non-obvious positive, relatively high gains were found for dihydroceramide synthase (*X*~112~), dihydroceramide hydroxylase (*X*~115~), and Ipc1 (*X*~121~); increases in their activities result in changes in phytoceramide levels. High negative gains were seen for dihydroceramide ceramidase (*X*~110~), phytoceramidase (*X*~113~), hydroxylase (*X*~114~); increases in their activities result in decreases in phytoceramide levels. Of interest is that none of the gains are extraordinarily high and that gains with respect to Pma1 are largely unremarkable. A similar analysis of flux gains did not add further insight. The log gains are closely related to kinetic parameter sensitivities, which were therefore, not surprisingly, not remarkable either.

The gains provided us with modest insights into which metabolites are most affected by changes in particular enzymes and transport steps. However, they did not reveal compelling explanations of how *Cn* coordinates responses to shifts in pH. Therefore, we used simulations to explore mechanisms of proton handling and the role of alterations in Ipc1 and Isc1 in these mechanisms. All analyses were executed with the free software PLAS^©^ ([@b19]). The Isc1 simulation was made with a 95% decrease in activity and Ipc1 perturbations were implemented with 85% decreases. These alterations were initiated in the simulations at time 1 min. We selected for our discussion of results the simulations most relevant for the analysis of regulation of Pma1 by phytoceramide with respect to internal proton concentrations.

Effect of decreased Isc1 (*X*~119~)
-----------------------------------

The 'static\' gain analysis was not able to rationalize the means by which *Cn* responds to shifts in pH. Because our biological experiments pointed to Isc1 and Ipc1 as potential contributors to the acidity response, we simulated changes in their activities, which in reality would probably be achieved through alterations in gene expression, following sensing and signal transduction.

[Figure 2](#f2){ref-type="fig"} shows the responses to a 95% decrease in Isc1 activity. The transients in this figure are not as important as the final state of the system, because we are modeling an 'inborn\' mutation, as opposed to something like a sudden change in substrate. It is evident that phytoceramide C~26~ (*X*~9~) and ATP (*X*~17~) levels are dramatically and permanently decreased in this situation. Other key sphingolipids (*X*~1~*--X*~7~, *X*~4~--*X*~15~, and *X*~18~) are not significantly affected by this perturbation. By contrast, loss of Isc1 activity severely diminishes Pma1 activity (*X*~12~), and the cytoplasmic pH decreases from 6.5 to 3.6 and does not return to its nominal state, in which Isc1 shows normal activity.

Effect of decreased Ipc1 (*X*~121~) activity
--------------------------------------------

Decreases in the activity of Ipc1 (*X*~121~) similarly affect Pma1 function (see [Figure 3](#f3){ref-type="fig"} for the consequences of a 85% decrease). In this simulation of a low-pH environment, IPC-C~26~ (*X*~13~), phytoceramide C~18~ (*X*~11~), and Pma1 (*X*~12~) decrease, whereas phytoceramide C~26~ (*X*~9~) increases. The intracellular pH decreases from 6.5 to 5.4 and does not return to its normal state.

Validation of the model
=======================

The biochemical conditions considered in the model support the simplified scheme ([Figure 1](#f1){ref-type="fig"}) of sphingolipid metabolism in *Cn* in acid and neutral pH environments and allow us to predict how changes are transduced to Pma1 activity. As the model predictions are very specific, it is not difficult in this particular case to test some of them in the laboratory. In other words, the model effectively narrowed the range of most promising experimental targets from potentially very many to just a few. [Table III](#t3){ref-type="table"} shows comparisons between model deductions and observations.

According to mass spectrometric measurements, *Cn* WT produces more phytoceramide C~26~ in acidic compared to neutral conditions ([Table I](#t1){ref-type="table"}), but the same amounts of DAG (data not shown). Our early experiments (see 'Experimental studies identifying Ipc1, Isc1, and phytoceramide as drivers of pH response\') had suggested that both Ipc1 and Isc1 regulate Pma1 function. Moreover, it seems that the level of very long-chain phytoceramides is highly regulated by Isc1 but not by Ipc1 ([Table IV](#t4){ref-type="table"}). These experimental findings were tested against model predictions. For technical reasons, these tests were most reliably executed by comparing model results with experimental data for ATP and lipid measurements.

As ATP is required for Pma1 activity, we wondered whether deletion of Isc1 or downregulation of Ipc1 would affect the intracellular level of ATP. We found that the ATP level is dramatically reduced when Isc1 is deleted, compared to WT strain, but only in acidic and not neutral pH at 12, 24, and 48 h of growth (*P*\<0.05) ([Figure 4](#f4){ref-type="fig"}). Interestingly, downregulation of Ipc1 does not affect ATP levels at neutral (data not shown) or acidic conditions ([Table III](#t3){ref-type="table"}). The model predicts a 65% decrease in the ATP level in the Isc1 mutant, and the experimental data show an 80% decrease. At the same time, the model predicts no change in the ATP level upon Ipc1 downregulation, and the experimental results show no changes in ATP when Ipc1 activity is downregulated ([Table III](#t3){ref-type="table"} and [Figure 4](#f4){ref-type="fig"}).

Next, we performed lipid measurements in conditions where Ipc1 was downregulated or Isc1 deleted. Loss of Isc1 leads to a specific depletion of phytoceramide C~26~, especially at pH 4, whereas no changes are observed with phytoceramide C~18~ ([Table IV](#t4){ref-type="table"}) or other subspecies (data not shown). Interestingly, loss of Isc1 leads to an increase of C~16:1/18:1~-DAG in neutral but not acidic pH (data not shown). Downregulation of Ipc1 increases phytoceramide C~26~ compared to the WT strain at acidic pH but only at 48 h of growth ([Table IV](#t4){ref-type="table"}). At neutral pH, phytoceramide C~26~ does not change when Ipc1 is downregulated compared with WT ([Table IV](#t4){ref-type="table"}). The total DAG level decreases when Ipc1 is downregulated ([@b29], [@b28]), especially in the form of the Di-C~16~ DAG subspecies (data not shown). These results suggest that Isc1 specifically produces phytoceramide C~26~, which implies that it prefers IPC-C~26~ and/or C~26~ MIPC and/or C~26~-MIP2C compared to other complex sphingolipid substrates. By contrast, Ipc1 seems to use mainly phytoceramide C~18~ as a substrate and it appears that a rearrangement of phytoceramide species will occur at low pH ([Table IV](#t4){ref-type="table"}).

Finally, we measured the activity of Pma1 in *Cn* WT and mutant strains grown at pH 7.0 or 4.0. Pma1 activity was measured in extracted cell membranes by using an established protocol previously described for *Cn* ([@b62]). We then calculated *V*~max~ and *K*~M~ of Pma1 using the Lineweaver--Burk method, which linearizes the Michaelis--Menten equation by taking the reciprocal of both sides of the equation 1/*v*~0~=1/*V*~max~+(*K*~M~*/V*~max~)(1/\[S\])). We found that the *K*~M~ of Pma1 increased by ∼9- and ∼7-fold in Δ*isc1* and *GAL7:IPC1* mutants grown at pH 4.0, respectively, compared to WT or Δ*isc1-Rec*, whereas no significant changes were observed in *V*~max~ ([Table V](#t5){ref-type="table"}). A slightly increased value of *K*~M~ in the mutants was also present when strains were grown at pH 7.0, but the difference was not significant (data not shown). These results suggest that the affinity of Pma1 for ATP is dramatically reduced when Isc1 is deleted or Ipc1 downregulated.

Perhaps the oligomerization of Pma1 is impaired in the mutants compared to control strains and this effect is particularly present at pH 4.0. These results strongly validate our model in which very long-chain phytoceramides, such as the product of Isc1 phytoceramide C~26~, are predicted to regulate Pma1 oligomerization. They also suggest, however, that very long-chain phytoceramides are not the only regulators of Pma1 because Pma1 activity is also impaired in the *GAL7:IPC1* strain in which phytoceramide C~26~ level is normal.

Discussion
==========

This article presents a mathematical model that provides rationale for some expected and some counterintuitive changes in the sphingolipid pathway of *Cn* under neutral and acidic environments. The model focuses in particular on the metabolism of phytoceramides and predicts specifically that certain phytoceramide subspecies (C~26~) play a key role in the regulation of adaptation of *Cn* to low pH. To our knowledge, this is the first mathematical model proposed for *Cn* pathogenesis. While no model can be proved to be 'correct,\' our results indicate that the model is quite robust and accurate because all model predictions tested so far were validated successfully.

We experimentally confirmed that the concentration of phytoceramides is affected when cells are shifted from a neutral to an acidic environment. In acidic pH, the phytoceramide C~26~ subspecies increase compared to other subspecies and the production of phytoceramide C~26~ at low pH appears to be dependent on Isc1 activity. In conditions in which most Isc1 activity is lost, phytoceramide C~26~ cannot be formed and the intracellular ATP concentration is low. As a consequence, Pma1 activity is impaired by decreasing the affinity to the substrate. Under these conditions, cells exposed to an acidic environment do not die but, interestingly, need additional time to adapt before they can grow.

The transformation of complex sphingolipids into phytoceramide by the action of *Isc1* is a process that mainly occurs in the ER but can also occur in other organelles. For instance, it was suggested that, in addition to ER localization, Isc1 in *Sc* may also be localized in the mitochondria ([@b66]). This localization hypothesis is supported by mammalian studies in which sphingomyelinase, the counterpart of *Isc1* in mammalian cells, is localized in the mitochondria in addition to the ER ([@b9], [@b10]). In addition, recent studies showed that Isc1 produces phytoceramides in mitochondria, in particular α-hydroxylated phytoceramide C~26~ but also other species such as non-hydroxylated phytoceramides C~18,~ C~24~, and C~26~ ([@b31]). Production of these sphingolipids by Isc1 implies that IPCs formed in the Golgi apparatus are transported to the ER. Currently, it is not known whether complex sphingolipid transport occurs, but since the transport of phospholipids between mitochondria and the ER can occur through membrane association ([@b1]), it is possible that IPCs could be transported as well.

In the mitochondrial membrane, the degradation of IPCs into phytoceramides may have important consequences for the membrane potential and the generation of ATP. In our system, the reduction of ATP level in the absence of *Isc1* suggests a potential role of *Isc1* in mitochondria in the regulation of ATP synthesis.

In conditions in which Ipc1 is downregulated, yeast cells also need additional time to adapt but this initial adaptation appears to be independent of phytoceramide C~26~. Indeed, the level of phytoceramide C~26~ does not decrease upon downregulation of Ipc1 but, instead, increases at low pH. Thus, it is proposed that Ipc1 regulates growth at low pH and Pma1 activity through the formation of IPC and/or DAG. IPC is a complex sphingolipid that is important for the integrity of the plasma membrane, whereas DAG produced by Ipc1 is important for the activation of Pkc1 and the consequent cell wall integrity ([@b29], [@b28]). Cell wall integrity, regulated by the Ipc1--DAG--Pkc1 pathway, is required for the proper function of the laccase enzyme in *Cn* ([@b28]) and it may also be important for the proper localization and/or oligomerization of Pma1 in the plasma membrane.

On the other hand, a relationship between Pma1 biogenesis and lipid synthesis is indicated by a number of observations. Lipids containing C~26~ fatty acids, either phytoceramide or glycerophospholipid bound, are important for stable biogenesis of Pma1 ([@b64], [@b65]). Phytoceramide synthesis is also required for oligomerization and raft association of Pma1 in the ER ([@b33]; [@b70]), and oligomerization of Pma1 could be important for stabilization of the protein once it has reached the cell surface ([@b70]). Other studies also suggest that the synthesis of complex sphingolipids is critically important for Pma1 biogenesis ([@b23]). Indeed, in *Sc*, a decrease in proton extrusion by Pma1 is observed in the absence of complex sphingolipids, suggesting that IPC, MIPC, and M(IP)~2~C may regulate Pma1 function ([@b1]). The fact that Isc1 and Ipc1 activities are required for Pma1 stability is supported by the observation that, in conditions in which Isc1 is deleted or Ipc1 downregulated, the mutant is hypersensitive to ebselen and the *K*~M~ of Pma1 significantly increased. Our results are in concordance with yeast studies by [@b46], in which sphingolipid deficiency causes a deficiency in net proton extrusion under acidic pH. More recent studies show that if Pma1 is not directly complexed with very long-chain phytoceramide, its function may be lost and the cells are unable to grow at low pH ([@b24]).

Based on our simulations, the model suggests that Pma1 activity decreases when Isc1 is deleted or Ipc1 is downregulated, and our experimental findings demonstrated this model prediction. Specifically, the model suggests that Isc1 and Ipc1 regulate Pma1 through different mechanisms: Isc1 through phytoceramide C~26~ and Ipc1 through IPC and/or DAG. Under acidic conditions, the cells require additional production of phytoceramide C~26~. This is readily achievable by metabolizing IPC-C~26~ into phytoceramide C~26~ by the action of Isc1. Under conditions in which Isc1 is deleted, the cells need more time to adapt to the acidic environment and to grow successfully. Eventually they do, perhaps through the overproduction of specific subspecies of DAG, which was observed at 24 and 48 h when Isc1 is deleted. This overproduction of DAG and the consequent stabilization of cell wall integrity by Pkc1 may eventually compensate for the lack of phytoceramide C~26~ and the dysfunction of Pma1.

Under conditions in which Ipc1 is downregulated, the cells also need more time to adapt to the acidic environment before they can restore growth. In these cases, IPC and DAG levels decrease and phytoceramide level increases ([@b28]). Interestingly, phytoceramide C~18~ increases at neutral pH, whereas phytoceramide C~26~ increases at 48 h of incubation at low pH ([Table IV](#t4){ref-type="table"}). This increase could reflect a compensatory mechanism triggered by the Ipc1 mutant strain to restore growth under low pH. Indeed, phytoceramide C~26~ increases only at low but not neutral pH. Perhaps, Isc1, which according to our data is the key regulator of phytoceramide C~26~ level, compensates by increasing its activity in conditions where Ipc1-downregulated cells suffer from the lack of IPC and/or DAG. The model also predicts an increase in PHS during Ipc1 downregulation at mid- to late-log phase and under acidic external conditions (data not shown). Indeed, accumulation of PHS was also observed experimentally when Ipc1 was downregulated (data not shown), suggesting that other mechanisms for the Ipc1--Pma1 regulation may exist in addition to IPC and/or DAG.

The analysis of which genes and enzymes associated with sphingolipid and other pathways are most important for fungal cell homeostasis under certain growth conditions may have important medical implications. For instance, one could evaluate the level of expression of a specific gene or enzyme in fungal cells isolated from patients and establish to what degree the *in vivo* expression would differ in different patients. During infection, *Cn* cells may reside extracellularly and intracellularly, and the percentage of *Cn* cells in each compartment is most likely to vary for a number of reasons (e.g., expression of specific fungal virulence factors, such as capsule, melanin, glucosylceramide, antiphagocytic protein 1 (App1), phospholipase B1 (Plb1), urease, availability of host cells for intracellular growth, and the status of the host immune response). In cases of host immunodeficiency, *Cn* cells may prefer to reside in one compartment (e.g., intracellular) instead of the other (extracellular), and gene expression and/or protein activities in intracellular *Cn* may be completely different compared to extracellular *Cn* ([@b17]). Thus, if information related to a specific gene expression or protein activity could be evaluated by a mathematical model in cells recovered from a patient, then we could predict the overall fitness of the fungus during a particular time of infection. For instance, overexpression of Isc1 or an elevated level of phytoceramide C~26~ would predict an intracellular localization of *Cn*, whereas overexpression of glucosylceramide synthase and downregulation of Ipc1 and/or Isc1 would predict an extracellular localization. Such an analysis might have important implications for the outcome of the infection because we know that the different localization (intracellular versus extracellular) of fungal cells may affect the pathogenesis of *Cn* infection ([@b54]; [@b61]) and its susceptibility to antifungal treatment. For instance, chloroquine increases the efficacy of fluconazole by alkalinizing the intracellular compartment and favoring the extrusion of *Cn* cells into the extracellular space ([@b43]; [@b30]; [@b5]; [@b38]). Thus, mathematical models accounting for *Cn* gene expression profiles and enzymatic activities at a specific time of the infection may help to define the context (host immunity) and the space (extracellular or intracellular) in which the infection occurs in a specific patient. It is through a combination of targeted, reductionistic molecular biology and system-wide computational biology that this goal may be achieved.

Materials and methods
=====================

Biochemical systems theory
--------------------------

BST has been reviewed numerous times in the recent literature ([@b68]; [@b63]), and we will discuss only its most salient features. The starting point is the description of temporal changes in each of the dependent variables *X*~*i*~ in a biochemical system with the general system equation

Here, *V*~*i*~^+^ and *V*~*i*~^−^ are positive valued functions that may involve some or all of the system variables *X*~1~, *X*~2~, ..., *X*~*n*+*m*~. The first *n* variables typically change over time, whereas the remaining *m* are considered constant during each mathematical experiment, but may change from one experiment to the next. The key feature of BST is the representation of the functions *V*~*i*~^+^ and *V*~*i*~^−^ as products of power-law functions ([@b56], [@b57]). In the so-called S-system form, which we will use here, the dynamics of each dynamic variable is thus formulated as

The parameters α~*i*~ and β~*i*~ are non-negative rate constants, and *g*~*ij*~ and *h*~*ij*~ are real-valued kinetic orders. The parameters *α*~*i*~ and *g*~*ij*~ are associated with the aggregate rate law *V*~*i*~^+^ for synthesis or augmentation of *X*~*i*~, whereas β~*i*~ and *h*~*ij*~ are associated with the aggregate rate law *V*~*i*~^−^ for degradation or elimination of *X*~*i*~.

Details of model design, estimation of parameter values, and conversions between this and other model types are presented in [Supplementary information](#S1){ref-type="supplementary-material"}. Simulations, stability and sensitivity analysis, as well as the assessment of gains were executed with the free software PLAS^©^ ([@b19]). Results that are not of prime interest here are presented in [Supplementary information](#S1){ref-type="supplementary-material"}. Suffice it to say that the model has a stable steady state, that it is overall very robust, and that no obvious reasons to worry about its properties were detected in extensive diagnostic studies.

Strains and growth conditions
-----------------------------

*Cn* var. *grubii* serotype A strain H99 (WT), *Cn GAL7:IPC1* ([@b37]) strain, Δ*isc1* mutant, and the Δ*isc1*+*ISC1* (Δ*isc1*^REC^) strains ([@b61]) were used in this study. Strains were routinely grown in yeast extract/peptone/dextrose (YPD) (Difco) medium buffered to pH 7.0 or 4.0 with 25 mM HEPES. Yeast nitrogen base (YNB) was composed of 6.7 g/l yeast nitrogen base (Difco) with amino acids and 5 g/l glucose. To downregulate Ipc1, the *GAL7:IPC1* strain was grown on glucose medium as previously described ([@b37]; [@b41]).

Extraction and analysis of yeast sphingolipids
----------------------------------------------

Strains were grown in YPD at pH 7.0 for 24 h, washed twice with sterile distilled water, and inoculated into fresh YPD pH 7.0 or 4.0 media. At appropriate time points (0, 6, 12, 24, and 48 h), cells were collected by centrifugation at 3000 r.p.m. for 10 min, washed twice with sterile distilled water, and the pellets were stored at −80°C. Neutral lipids were extracted by the method of [@b11]. An aliquot of the extraction (300 μl) was used for phosphorous determination ([@b50]). Internal standards were added to the remaining aliquots, and sphingolipids were extracted in a one-phase neutral organic solvent (propan-2-ol/water/ethyl acetate, 30:10:60, v/v). Samples were then analyzed by a Surveyor/TSQ 7000 liquid chromatography--MS system. Lipids were qualitatively defined by parent-ion scanning for known fragments characteristic for a specific sphingolipid class, including sphingoid bases, ceramides, and phytoceramides. For all experiments, source ion optics was adjusted to accomplish desolvation of ions while minimizing fragmentation of ions in the inlet region of the mass spectrometer ([@b51]). Samples were quantitatively analyzed on the basis of calibration curves generated with synthetic standards. The mass of each species was normalized to phosphorous levels of each sample.

Growth inhibition
-----------------

Experiments to determine MICs and MFCs were performed by the broth microdilution method according to the recommendations of the National Committee for Clinical Laboratory Standards ([@b45]). *Cn* strains were grown in YPD (pH 7.0) for 24 h at 30°C. Cells were washed twice with sterile deionized water, and the density was adjusted to a final concentration of 2.5 × 10^3^ cells/ml in YNB with 25 mM HEPES at a pH of 7.0 or 4.0. Ebselen was obtained from Sigma. The MIC was defined as the lowest drug concentration in which a visual turbidity of ⩽80% inhibition was observed compared to that produced by the growth control. One hundred microliter aliquots from wells with growth inhibition were plated onto YPD agar plates. The lowest concentration that yielded three or fewer colonies was recorded as the MFC.

Measurement of ATP level
------------------------

Intracellular ATP concentrations were determined by using a bioluminescent ATP assay kit (Sigma), which measures the conversion of luciferin to light by firefly luciferase in the presence of ATP. The light emitted is proportional to the ATP present and was measured at 490 nm using a luminometer (Berthold Australia Pty Ltd, Bundoora, Australia). *Cn* WT, Δ*isc1*, Δ*isc1*^*REC*^, or *GAL7:IPC1* strains were grown in 40 ml of YNB containing 2% glucose with 25 mM HEPES (pH 7.0 or 4.0) for 12, 24, or 48 h. Cells were washed twice with sterile deionized water. A pellet containing 5 × 10^8^ cryptococcal cells was flash-frozen and stored at −80°C. Pellets were resuspended in 800 μl of 50 mM HEPES (pH 7.75) and 200 μl DMSO. Acid-washed glass beads were added and cells were homogenized five times for 45 s each using the Bead-Beader-8, with samples being kept on ice for at least 1 min between homogenization cycles. After centrifugation at 2500 *g* for 10 min at 4°C, the supernatant was collected to determine ATP concentrations according to the manufacturer\'s instructions. Protein concentration of an aliquot of the supernatant was measured by the Bradford method and was used to normalize ATP determination to control for the extraction process.

Pma1 activity
-------------

Plasma membranes were isolated from *Cn* WT, Δ*isc1*, Δ*isc1-Rec*, and *GAL7:IPC1* strains grown in 250 ml YNB containing 2% dextrose with 25 mM HEPES (pH 4 or 7) for 24 h. The membranes for each strain were isolated by the procedure described by [@b69]. Specifically, the cells were resuspended in 25 ml homogenization buffer consisting of 100 mM Tris--HCl, pH 7.5, 5 mM EDTA, 5 mg/ml bovine serum albumin, and 1 mM phenylmethylsulfonyl fluoride, which was added just before use. The cells were passed through a French pressure cell at 20 000 p.s.i. at 4°C. The lysate was adjusted to pH 7 with 1 M HCl and centrifuged at 10 000 *g* for 10 min. The resulting supernatant was centrifuged at 100 000 *g* for 60 min and the pellet was resuspended in 3 ml extraction buffer consisting of 10 mM HEPES--KOH, pH 7.0, 100 mM KCl, 0.2 mM EDTA, 1 mM dithiothreitol, and 0.45% (w/v) glycerol by sonication for 3 × 15 s (15% amplitude). Deoxycholate (10% w/v stock) was added to the suspension on ice to a final concentration of 0.5% w/v. This suspension was then centrifuged at 150 000 *g* for 1 h. The pellet was washed by resuspension (via sonication) in extraction buffer (3 ml) and centrifuged at 150 000 *g* for 1 h. The final pellet was resuspended in 1.5 ml extraction buffer. Protein determination was carried out using the Bradford method with bovine serum albumin as the standard. ATPase assays were conducted in 96-well microtiter plates similar to the method described by [@b69]. Briefly, a 125 μl assay mixture contained 10 mM MES--Tris, pH 6.5, 0--14 mM MgSO~4~, 25 mM NH~4~Cl, 0--14 mM ATP, and 0.6--1 μg membrane protein. Samples were incubated at 30°C for 15 min and inorganic phosphate released from ATP was determined by the addition of 125 μl of phosphate developing reagent, consisting of 0.6 M H~2~SO~4~, 9% [L]{.smallcaps}-ascorbic acid, and 0.9% ammonium molybdate. The absorbance at 820 nm was determined after 10 min incubation at room temperature. The amount of phosphate liberated was estimated by using a linear standard curve in the range 0--100 μM NaH~2~PO~4~. All *K*~M~ and *V*~max~ values were obtained by determining ATP hydrolysis as a function of substrate concentration (0--14 mM for both ATP and MgSO~4~) and the data were fit to the Michaelis--Menten equation.
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![Model diagram of sphingolipid metabolism in *Cn*. Metabolites in boxes represent dependent variables that are defined through differential equations and are numbered from *X*~1~ to *X*~19~. Independent variables are numbered from *X*~100~ to *X*~136~. Solid arrows show flow of material. Plus signs associated with dotted arrows represent activation. The acylation state is coded as (1) *C*~26~*-CoA*, (2) *C*~18~*-CoA*, and (3) *C*~24~*-CoA*; these are substrates for the *DH-Cer synthase* reaction or for the enzyme *P-Cer synthase* (see main text and [Supplementary information](#S1){ref-type="supplementary-material"} for details). Dependent variables: Pal-CoA (*X*~1~), palmitoyl-CoA; serine (*X*~2~); KDHS (*X*~3~), 3-ketodihydrosphingosine; DHS (*X*~4~), dihydrosphingosine; dihydro-C~24~ (*X*~5~), dihydroceramide C~24~; dihydro-C~26~ (*X*~6~), dihydroceramide C~26~; dihydro-C~18~ (*X*~7~), dihydroceramide C~18~; PHS (*X*~8~), phytosphingosine; phyto-C~26~ (*X*~9~), phytoceramide C~26~; phyto-C~24~ (*X*~10~), phytoceramide C~24~; phyto-C~18~ (*X*~11~), phytoceramide C~18~; Pma1 (*X*~12~), newly synthesized Pma1; IPC-C~26~ (*X*~13~), inositol phosphorylceramide C~26~; IPC-C~24~ (*X*~14~), inositol phosphorylceramide C~24~; IPC-C~18~ (*X*~15~), inositol phosphorylceramide C~18~; intracellular protons (*X*~16~); ATP (*X*~17~), adenosine-5′-triphosphate; palmitate (*X*~18~); DAG (*X*~19~), *sn*-1,2-diacylglycerol. Independent variables: *palmitate ext* (*X*~100~), *palmitate external*; *serine ext* (*X*~101~), *serine external*; *palmitate transport* (*X*~102~); *serine transport* (*X*~103~); *Ac-CoA* (*X*~104~), *acetyl CoA*; *C*~26~*-CoA* (*X*~105~), *very long-chain fatty acid* (*C*~26~*-CoA*); *C*~18~*-CoA* (*X*~106~), *fatty acid* (*C*~18~*-CoA*); *C*~24~*-CoA* (*X*~107~), *fatty acid* (*C*~24~*-CoA*); *serine palmitoyltransferase* (*X*~108~); *ADP*, *adenosine biphosphate* (*X*~109~); *dihydro-CDase* (*X*~110~), *dihydroceramide ceramidase*; *KDHS reductase* (*X*~111~), *3-ketodihydrosphingosine reductase*; *DH-Cer synthase* (*X*~112~), *dihydroceramide synthase*; *phyto-CDase* (*X*~113~), phytoceramidase; *hydroxylase* (*X*~114~); *hydroxylase* (*X*~115~); *P-Cer synthase* (*X*~116~), *phytoceramide synthase*; *Pma1p* (*X*~117~), *newly synthesized Pma1 in the ER*; *Sec61* (*X*~118~), *Sec61 as probable ER insertion protein*; *Isc1* (*X*~119~), *inositol phosphosphingolipid phospholipase C*; *PI* (*X*~120~), *phosphatidylinositol*; *Ipc1* (*X*~121~), *inositol phosphorylceramide synthase*; *alternative respiration* (*X*~122~); *NADHm* (*X*~123~), *nicotinamide adenine dinucleotide*; *oxygen* (*X*~124~); *Pma1-H*^+^*ATPase* (*X*~125~), *synthesized plasma membrane H*^+^*-ATPase*; *H*^+^ (*X*~126~), *protons external*; *ER--Golgi transport* (*X*~127~); *H*^+^ *transport* (*X*~128~), *proton transport*; *SHMT* (*X*~129~) *serine hydroxymethyl transferase*; *Golgi membrane* (*X*~130~); *Pal-CoA synthase* (*X*~131~), *palmitoyl-CoA synthase*; *ATP total* (*X*~132~); *AMP* (*X*~133~), *adenosine monophosphate*; *Golgi--ER transport* (*X*~134~); *F*~0~*F*~1~*-ATPase* (*X*~135~), *F*~0~*F*~1~*-ATP synthase*; *H*^+^ *m* (*X*~136~), *mitochondrial protons.*](msb200817-f1){#f1}

![Simulation result of a 95% decrease in Isc1 (*X*~119~) activity. Phyto-C~26~ (*X*~9~), Pma1 (*X*~12~), and ATP (*X*~17~) decrease. The remaining metabolites stay close to their initial values, except for IPC-C~26~ (*X*~13~), which increases. The intracellular pH decreases from 6.5 to 3.6.](msb200817-f2){#f2}

![Simulation result of an 85% decrease in Ipc1 (*X*~121~) activity. Phyto-C~18~ (*X*~11~), IPC-C~26~ (*X*~13~), and Pma1 (*X*~12~) decrease, whereas phyto-C~26~ (*X*~9~) and phyto-C~24~ (*X*~10~) increase. The remaining metabolites stay close to their initial values. The intracellular pH decreases from 6.5 to 5.4.](msb200817-f3){#f3}

![Measurement of intracellular ATP in Δ*isc1* mutant and control strains during growth at neutral and acidic pH. (**A**) Production of ATP is not impaired in the Δ*isc1* strain when exposed to a neutral pH environment. (**B**) Production of ATP is significantly impaired in the Δ*isc1* strain when exposed to a low-pH environment. Values are reported as pmol/μg protein. Results are means±s.d. of three separate experiments. ^\*^*P*\<0.05, Δ*isc1* versus WT.](msb200817-f4){#f4}

###### 

Identification of ceramide species at 48 h of growth

  Ceramide species (pmol/pmol P~i~)                                                                                              
  ----------------------------------- ------- ----- --------- --------- ------- ------- ----------- ----- ------ ----- --------- -----
  pH 7                                 406.6   230     60       2260     640.1    170       96       3.1   1.04   570     360     310
  pH 4                                 215.3   180   4.5^\*^   396^\*^    400    222.5   170.4^\*^   4.2    3     810   710^\*^   620

^\*^*P*\<0.05 (pH 4 versus 7).

Mass spectrometric analysis of different phytoceramide and alpha hydroxyl phytoceramide species during late-log phase in a *Cn* H99 WT strain. Determinations are to neutral pH or acidic pH. The mass of each species was normalized to phosphorous levels of each sample. Results are the means of three separate experiments. The concentrations are reported as pmol/pmol P~i~ for phyto- (phytoceramide) and α-OH-phyto (alpha hydroxyl phytoceramide) with different length fatty acid chains.

###### 

Loss of Isc1 sensitizes *Cn* to the Pma1 inhibitor ebselen[^a^](#t2-fn2){ref-type="fn"}

  Strain                 pH 7 (μM)   pH 4 (μM)
  --------------------- ----------- -----------
  WT                       3.12        2.48
  Δ*isc1*                  3.12      0.78^\*^
  Δ*isc1*^*REC*^           3.12        3.12
  *GAL7:IPC1-*glucose      3.12      0.39^\*^

^\*^*P*\<0.05 (pH 4 versus 7).

^a^Ebselen is fungicidal to WT, Δ*isc1*, Δ*isc1^REC^*, and *GAL7:IPC1* strains at an MFC of 3.12 μM at a neutral pH. The Δ*isc1* mutant and *GAL7:IPC1* strain grown on glucose (Ipc1 downregulated) showed MFCs of 0.78 and 0.39 μM, respectively. Results are the means of three separate experiments.

###### 

Comparison between model predictions and experimental data for acidic pH at 48 h of growth

  Metabolite                                     WT     Experimental data (pmol/pmol P~i~)   Model predictions (pmol/pmol P~i~)           
  -------------------------------------------- ------- ------------------------------------ ------------------------------------ -------- --------
  Phytoceramide C~26~ (*X*~9~)                  222.5                 523.3                                  10                   465.08    9.37
  Phytoceramide C~18~ (*X*~11~)                 215.3                 114.6                                 235                   179.65   173.80
  ATP (*X*~17~)[^a^](#t3-fn1){ref-type="fn"}    82.48                 80.36                              16.92^\*^                82.48    29.17

^a^pmol/μg protein.

^\*^*P*\<0.05, Δ*isc1* versus WT.

Phytoceramide C~26~ level is increased when Ipc1 is downregulated in the *GAL7:IPC1-*glucose strain compared to the control WT strains at pH 4. Values are concentrations in pmol phytoceramide C~18~ or C~26~/pmol phosphate (P~i~). Results shown are the means of three independent experiments. ATP is significantly lower in the Δ*isc1* mutant compared to the control strain (WT) at pH 4.

###### 

Experimental measurements of phytoceramides C~18~ and C~26~ in *Cn* WT, *GAL7:IPC1*, and Δ*isc1* mutant strains during *in vitro* growth at neutral and acidic pH

  Parameter       12 h   24 h    48 h                                         
  -------------- ------ ------ -------- ----- ------ -------- ------- ------- --------
  *pH 7*                                                                      
   Phyto-C~18~    482    1333    430     517   1090    530     406.6    900     980
   Phyto-C~26~    225    244    75^\*^   280   263    40^\*^    170     245     150
                                                                                  
  *PH 4*                                                                      
   Phyto-C~18~    207    45.2    180     220   96.6    240     215.3   114.6    235
   Phyto-C~26~    340    320    20^\*^   443   470    10^\*^   222.5   523.3   10^\*^

Ipc1 is downregulated in the *GAL7:IPC1-*glucose strain and Isc1 is deleted in the Δ*isc1* strain. Downregulation of Ipc1 shows an increase of phytoceramide C~18~ (phyto-C~18~) at neutral pH. In contrast, phytoceramide C~26~ (phyto-C~26~) is slightly increased in *GAL7:IPC1* compared to WT strain at acidic pH but only at 48 h of growth.

The level of phytoceramide C~26~ is significantly reduced in the Δ*isc1* mutant compared to the WT strain (^\*^*P*\<0.05). Measurements of phytoceramides C~18~ and C~26~ were also performed in the Δ*isc1*-reconstituted strain, and no significant differences were found in comparison with the WT strain (data not shown). Values are concentrations in pmol phytoceramide C~18~ or C~26~/pmol phosphate (P~i~). Results shown are the means of three independent experiments.

###### 

Experimental measurement of *K*~M~ and *V*~max~ of Pma1 in *Cn* WT, Δ*isc1*, Δ*isc1*-reconstituted (Δ*isc1*-Rec), and *GAL7:IPC1* strains in cell membranes extracted from cells grown at pH 4.0

                 pH 4.0  
  ------------- -------- ------
  WT              3.58    0.65
  Δ*isc1*         4.58    5.96
  Δ*isc1*-Rec     3.18    0.84
  *GAL7:IPC1*     4.64    6.21

*K*~M~ of Pma1 in Δ*isc1* and *GAL7:IPC1* strains increased by ∼9- and 7-fold respectively compared to the *K*~M~ of Pma1 in WT or Δ*isc1*-Rec strains. No significant changes were observed in *V*~max~. Also, no significant changes in *V*~max~ and *K*~M~ were observed when strains were grown at pH 7.0 (data not shown).
